EU expands use of Janssen’s Darzalex

2nd May 2017 Uncategorised 0

EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and dexamethasone, or bortezomib (Velcade).

More: EU expands use of Janssen’s Darzalex
Source: News